Will IVF Work for Me? Low AMH, PCOS, Endometriosis, Blocked Tubes and Low Sperm Count — Condition by Condition

By Dr. Shweta Agarwal, MBBS, DGO Medically reviewed by Dr. Shweta Agarwal, MBBS, DGO Last updated: July 2026

Information on this page is educational and does not replace a medical consultation. Outcomes depend on individual clinical factors.

Aansh Hospital & IVF Center is a government-registered Level-2 ART clinic (Reg. No. MH/AC/2024/15441/L2/Chandrapur/132), with our headquarters and in-house embryology lab in Chandrapur, serving patients across Vidarbha and northern Telangana. You can verify our government ART registration on the National ART & Surrogacy Registry.

Almost every first consultation contains the same question, phrased slightly differently: "Doctor, I have this problem — will IVF actually work for me?"

It is a fair question, and most of the internet answers it badly. Search "can IVF work with low AMH" or "does IVF work with endometriosis" and you will find a page per condition, each written by a different clinic, each ending with a success-rate figure that has no denominator attached to it. Nobody sets the conditions side by side, and nobody explains why the answer differs.

This guide does that. It takes the five diagnoses that account for most of what we see in the Chandrapur clinic — low AMH, PCOS, endometriosis, blocked tubes, and male factor — and explains what each one actually changes about an IVF cycle. It contains no Aansh success percentages, because a percentage without a denominator, an age band and a definition of "success" is a marketing number rather than a clinical one. If you want to know how to interrogate any figure a clinic quotes you, read How to Read an IVF Success-Rate Claim alongside this.

The four levers: a simple way to read your own diagnosis

Before the conditions, one framework that makes the rest of this page much easier to read. It is a simplification, not a complete account of why cycles succeed or fail — ovarian response, embryo development, uterine factors, general health and chance all sit alongside it.

An IVF cycle has to clear four broad steps, and most diagnoses act on one or two of them:

1. Egg number — how many mature eggs a stimulated cycle produces.
2. Egg quality — what proportion of those eggs are chromosomally normal. This tracks female age more than any other variable.
3. Fertilisation — whether sperm and egg combine to form a normally developing embryo.
4. Implantation — whether a good embryo attaches to a receptive uterine lining.

Here is roughly where each common diagnosis sits. "Not directly affected" means the diagnosis itself does not act on that step — other factors may still coexist in the same couple.

Read the table twice. The most useful thing in it is that the diagnoses patients fear most — blocked tubes, low sperm count — are the ones the technology addresses most directly, while the factor no technology reverses is age.

Can IVF work with low AMH?

Short answer: Yes. AMH predicts how your ovaries will respond to stimulation — how many eggs are likely to be collected — far better than it predicts whether a baby is possible. Egg quality tracks your age rather than your AMH. Low AMH usually means fewer eggs per retrieval, so the plan may need more than one retrieval before a transfer.

AMH (anti-Müllerian hormone) is produced by the small resting follicles in the ovaries, so the blood level reflects how many follicles are available to respond to stimulation. That is genuinely useful information — it is why we check it, alongside an antral follicle count on ultrasound, before planning any cycle.

What AMH does not do is measure the chromosomal competence of the eggs you have. ASRM's committee opinion on testing and interpreting measures of ovarian reserve is clear that these tests predict ovarian response, and that a low result on its own should not be used to deny treatment or to tell a woman she cannot conceive. There is a weak statistical association between AMH and live birth in treated populations — but that is a long way from a threshold.

What actually changes with low AMH:

• Protocol. Stimulation is individualised, and the honest position is that the evidence does not establish one best protocol for predicted poor responders. ESHRE's ovarian stimulation guidance does not support simply escalating gonadotropin doses without limit; higher doses beyond conventional maximums have not been shown to deliver more eggs in this group. Milder ("mini") stimulation, antagonist protocols and adjuvants are options that are discussed individually, not established solutions.
• Expected yield. Fewer eggs generally means fewer embryos, and therefore fewer chances per retrieval.
• Number of retrievals. Where a single retrieval produces very few embryos, some patients undergo more than one retrieval and freeze embryos before attempting a transfer. This increases the number of opportunities, but it also adds cost, time and physical burden — and it does not guarantee a live birth.
• Cancellation risk. A cycle that recruits too few follicles may be converted or cancelled. Ask your clinic in advance what happens financially if that occurs; our cost and EMI page sets out how our packages handle it.

There is no universal AMH cut-off below which IVF is refused. Any cut-off you are quoted describes a clinic's policy, not a biological boundary. If you have been told your AMH rules you out, that is precisely the situation a free second opinion exists for.

Read more on our low AMH and diminished ovarian reserve page, and on what the number means at each age in AMH levels by age.

Does IVF work with PCOS — and is IVF even the right first step?

Short answer: Yes, IVF is used successfully in PCOS, and PCOS ovaries usually produce more eggs than average. But IVF is often not the first treatment. Because the core problem is ovulation, many women conceive with ovulation induction alone. The main IVF-specific issue in PCOS is managing an excessive response and the risk of ovarian hyperstimulation syndrome (OHSS).

PCOS is a disorder of ovulation, not of egg supply. That has three practical consequences.

First, the treatment ladder starts lower. The 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome recommends letrozole as first-line pharmacological treatment for ovulation induction in women with PCOS and anovulatory infertility with no other infertility factors, with clomiphene as an alternative and metformin in selected situations. IUI and then IVF follow if ovulation induction does not achieve pregnancy, or if another factor is present — blocked tubes, significant male factor, or a long duration of infertility. Weight, insulin resistance and thyroid status are addressed in parallel, because they influence ovulation independently.

Second, stimulation has to be planned around the risk of over-response. PCOS ovaries typically contain a large number of small follicles and can respond excessively to gonadotropins. The complication being avoided is OHSS. Antagonist protocols and a GnRH-agonist trigger reduce that risk, and a freeze-all approach — embryos frozen and transferred in a later, unstimulated cycle — is used when clinically indicated. This is routine risk management, not a sign that something has gone wrong. Ask any clinic what their OHSS-prevention plan for you is; a clinic with no specific answer for a PCOS patient is one to ask more questions of.

Third, a high egg count is not automatically a high embryo count. In PCOS cycles a proportion of the eggs collected may be immature and unusable, so the number that fertilise normally can be lower than the retrieval number suggests. Expecting that in advance makes the day-after phone call less of a shock.

More on diagnosis and long-term management on our PCOS / PCOD page, and on the treatment-ladder decision in IVF vs IUI: how we decide.

Does IVF work with endometriosis?

Short answer: Yes — IVF is an established treatment for endometriosis-related infertility, and it bypasses the tubal and pelvic obstacles the disease creates. It does not remove every effect of endometriosis: ovarian reserve, endometriomas, previous ovarian surgery, inflammation and possible effects on implantation still shape the outcome. Prognosis is best judged individually, not from the diagnosis label alone.

Endometriosis can complicate fertility through several routes at once: distorted pelvic anatomy and adhesions, inflammation in the pelvic environment, reduced ovarian reserve where endometriomas or prior surgery have affected ovarian tissue, and possible effects on endometrial receptivity. IVF removes the dependence on tubal transport entirely — eggs are collected directly from the ovary and the embryo is placed directly into the uterus. It does not undo reduced ovarian reserve, and it does not make the retrieval technically simpler when the pelvis is heavily distorted.

That is why the surgery-versus-IVF sequence matters so much, and it is a genuinely difficult decision: repeated ovarian cystectomy for endometriomas carries a risk of further reducing reserve. ESHRE's endometriosis guideline advises against operating on endometriomas purely to improve ART live-birth outcomes, while recognising that surgery may still be appropriate for pain or for access to follicles. We have written the decision out in full in Surgery or straight to IVF? Tubes and endometriosis.

Two further questions patients ask:

• Does IVF make endometriosis worse? IVF stimulation raises oestrogen levels temporarily, which is a reasonable theoretical concern in an oestrogen-dependent disease. ESHRE's guidance supports reassuring patients that ART does not appear to increase endometriosis recurrence. Any pain flare during stimulation should still be reported so it can be managed.
• Is IVF better than IUI for endometriosis? There is no simple rule that a given stage means a given treatment. Where disease is advanced, where tubes are affected, or where other factors coexist, IVF is generally the more direct route; in minimal disease with open tubes and no male factor, expectant management or IUI may reasonably come first. The choice should be an individualised discussion, not a formula.

See our endometriosis page for symptoms, diagnosis and the full treatment picture.

Does IVF work with blocked fallopian tubes?

Short answer: Yes — blocked tubes are the original and most direct indication for IVF. The tubes exist to bring egg and sperm together and to carry the embryo to the uterus; IVF replaces both functions in the laboratory. If the tubes are the only problem, prognosis is driven by your age and ovarian reserve rather than by the blockage itself.

One important exception: hydrosalpinx, a tube blocked at its far end and distended with fluid. That fluid can track back into the uterine cavity, and it is well recognised that an untreated hydrosalpinx reduces the chance of a successful transfer. Cochrane's review of surgical treatment for tubal disease before IVF found that laparoscopic salpingectomy probably improves clinical pregnancy rates, with weaker evidence for proximal tubal occlusion and for aspiration, and limited live-birth data overall. Treating the affected tube before embryo transfer — usually by removal or clipping, with aspiration considered where laparoscopy is unsuitable — is standard practice. The ovary is a separate organ and continues to function after the tube is removed, though any pelvic surgery warrants an individual discussion of risks including its effect on ovarian blood supply.

Whether to attempt tubal surgery to restore natural fertility instead of proceeding to IVF depends on the type and site of the blockage, your age, and whether any other factor is present. Fine adhesions around otherwise healthy tubes in a younger woman may be worth releasing; badly damaged tubes are usually not, and surgery in that setting also carries a raised ectopic pregnancy risk. The comparison is set out in Surgery or straight to IVF?, and the test that usually identifies the blockage is described in HSG test: what to expect.

More on causes and options on our blocked fallopian tubes page.

Does IVF work for male infertility, and can IVF work with low sperm motility?

Short answer: In most cases, yes. Male factor affects fertilisation, and ICSI addresses that step by injecting a selected sperm directly into the egg, bypassing the need for sperm to swim to it and penetrate it. What is required is viable sperm, not a normal semen report. Egg quality, sperm DNA integrity and embryo development still influence the result.

This is the section where the internet is most misleading, because it repeats semen-analysis reference values as though they were IVF eligibility criteria. They are not. The WHO reference values describe the lower limits observed in men whose partners conceived naturally within a year. They describe natural conception. In the laboratory the requirement is different.

• Low motility. Conventional IVF — sperm and eggs placed together in a dish — does depend on sperm reaching and penetrating the egg, so significantly reduced motility is a real problem for that method. This is precisely why ICSI is chosen instead in significant male factor: the embryologist selects individual motile sperm and injects them. There is no published motility percentage below which treatment becomes impossible; what matters is whether viable sperm can be identified in the sample.
• Low count (oligozoospermia). The same logic applies. A cycle needs enough viable sperm to inject the mature eggs collected, which is a far smaller requirement than natural conception makes.
• Poor morphology (teratozoospermia). Morphology predicts natural and conventional-IVF fertilisation more than it predicts ICSI fertilisation. Isolated poor morphology with an otherwise normal count and motility is not by itself an established indication for ICSI, and ASRM's guidance on ICSI for non-male-factor indications reflects that the evidence of benefit in such cases is limited. The decision is made on the whole picture, not one line of the report.
• Azoospermia — "my husband has no sperm, how can I get pregnant?" No sperm in the ejaculate does not always mean no sperm production. In obstructive azoospermia, production is typically normal and sperm can usually be retrieved surgically (TESA/PESA) for ICSI. In non-obstructive azoospermia, sperm can still be found in a proportion of men by micro-TESE, and the chance depends on the underlying cause. Where no sperm can be retrieved, donor sperm through a registered ART bank is the remaining route under the ART (Regulation) Act 2021. Our azoospermia page covers the distinction and the tests that separate the two.
• High DNA fragmentation. Sperm DNA integrity is one of several factors ICSI does not correct, because the injected sperm still contributes its genome to the embryo. Testing (DFI) is used selectively where the history warrants it. The available interventions — lifestyle change, varicocele treatment, antioxidants, or the use of testicular rather than ejaculated sperm — are areas where the evidence remains limited, and none should be presented as an established fix.

One qualifier worth stating plainly: ICSI assists fertilisation. It does not improve egg quality, and it has not been shown to improve outcomes in couples without male factor. That is why we do not use it universally — the decision is set out in ICSI vs IVF: when is ICSI needed.

Start with an accurate baseline: what the numbers on a semen analysis mean, and our male infertility page.

At what age is IVF likely to fail, and what are the chances of IVF working at 45?

Short answer: There is no age at which IVF suddenly stops working. Live-birth rates using a woman's own eggs decline gradually from the early thirties and more steeply through the late thirties and forties. UK HFEA registry data reports live birth per embryo transferred in the mid-forties own-egg group in the low single digits, while donor-egg outcomes at the same recipient age are considerably higher.

Age is the one variable on this page that no protocol, supplement or laboratory technique reverses. The mechanism is chromosomal: the proportion of eggs with an abnormal chromosome count rises with maternal age, and aneuploid embryos either fail to implant or are lost as early miscarriages. That single mechanism explains both the falling pregnancy rate and the rising miscarriage rate in older patients.

Two cautions about any figure you read for this age group, including the one above. First, registry figures are published with a specific denominator — HFEA's headline numbers are per embryo transferred, not per cycle started, and the two are not interchangeable. Second, they are UK data; they describe a population, not you, and not India. They are useful as an order of magnitude and nothing more.

What this means practically in the mid-forties:

• Own-egg IVF is not impossible, but the chance per attempt is low, and the honest conversation is about how many attempts you are prepared for and what you will do if they do not work.
• More cycles add cumulative chance, but each cycle in this age band tends to yield fewer eggs and fewer chromosomally normal embryos, so the cumulative curve flattens.
• Donor egg IVF changes the prognosis substantially, because the embryos carry the donor's chromosomal profile while the uterus retains a relatively preserved capacity to carry a pregnancy. At Aansh this is offered only through our registered ART Bank (Reg. No. MH/AB/2024/11445/Chandrapur/91); donor recruitment, screening and matching must comply with the ART (Regulation) Act 2021, which permits ART services for a woman above the age of 21 and below the age of 50.
• Any clinic quoting you a strong success rate at 45 with your own eggs should be asked, precisely, for the denominator, the age band, and the number of cycles it was calculated from.

The biology is set out at length in IVF success and age: realistic expectations.

Is IVF more successful the second time? And what about the third?

Per-cycle success rates do not automatically rise with each attempt — but your cumulative chance of a live birth increases with every additional cycle, and a first failed cycle is genuinely informative in a way the first attempt could not be.

After one cycle we know things we could only estimate before: how the ovaries responded to a given dose, how many eggs matured, what proportion fertilised, how the embryos developed in culture, and what the endometrium looked like at transfer. Each of those is a lever that can be adjusted. Registry-based analyses of national datasets consistently show cumulative live-birth rates continuing to rise across successive cycles, with the largest gains in the earlier attempts — which is the strongest argument for planning treatment as a course rather than a single event, and why multi-cycle package structures exist.

Where good-quality embryos have been transferred without pregnancy, the picture changes and the investigation should widen. ESHRE's recommendations on recurrent implantation failure deliberately avoid a fixed "number of failed transfers" definition, framing it instead against the cumulative chance those particular embryos should have had — and they caution against routine immunological testing and treatment, with thrombophilia testing guided by personal and family history rather than performed for everyone. What should not happen is an identical further cycle run without anyone asking why the previous ones did not work. If that is where you are, bring your reports to a free second opinion. Our page on recurrent implantation failure explains the workup.

For the emotional side of that first negative, coming to terms after a failed IVF cycle may be more useful than any of the above.

When IVF is not the right first step

An honest condition-by-condition guide has to include the cases where the answer to "should I do IVF?" is "not yet".

• PCOS with no other factor. Ovulation induction, with weight and metabolic management, comes first.
• Mild male factor with open tubes and a younger female partner. IUI is often a reasonable and much less expensive first attempt.
• A short duration of trying, with no red flags. Investigation comes before treatment; the 12-month rule explains when that changes, and why the threshold is shorter with increasing female age.
• Untreated hydrosalpinx. Treat the tube before transferring an embryo.
• Uncontrolled thyroid disease or diabetes, or a very high or very low BMI. Correcting these first supports both treatment outcomes and pregnancy safety.
• No diagnosis yet. A complete workup for both partners — fertility testing 101 — should precede any treatment recommendation. If a clinic recommends IVF before a semen analysis has been done, that alone is a reason for a second opinion.

A note on one question that comes up in this district and has a legal rather than a clinical answer: sex selection of embryos is illegal in India under the PCPNDT Act, and no clinic may offer it for any reason. Anyone offering it is acting outside the law.

Talk it through with us

If you are holding a diagnosis and are not sure what it means for your chances, bring it to us. Dr. Shweta Agarwal offers a free second opinion — bring your AMH report, ultrasound, HSG, semen analysis, or a previous cycle summary from any clinic, and you will get an honest reading of what your reports actually say and what your realistic options are.

WhatsApp or call 80056 85160 to book. We are in Chandrapur with our own on-site embryology lab, so your samples and embryos never travel, and patients from Ballarpur, Bhadravati, Warora, Gadchiroli, Rajura and across Vidarbha are seen here without a trip to Nagpur or Hyderabad. Written cost estimates and 0% EMI options are set out on our costs and EMI page.

Sources referenced

• American Society for Reproductive Medicine (ASRM) — Practice Committee opinion on testing and interpreting measures of ovarian reserve (AMH and AFC predict ovarian response; a low result alone should not deny access to treatment).
• ASRM — Practice Committee opinion on intracytoplasmic sperm injection for non-male-factor indications (limited evidence of benefit outside male factor).
• ESHRE — guideline on ovarian stimulation for IVF/ICSI (individualised dosing; no established superior protocol for predicted poor responders).
• ESHRE — endometriosis guideline (surgery for endometrioma not recommended solely to improve ART live-birth outcomes; ART does not appear to increase recurrence).
• ESHRE — recommendations on recurrent implantation failure (individualised definition; immunological testing and treatment not routine).
• International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, 2023 (letrozole first-line for ovulation induction in anovulatory PCOS without other infertility factors).
• Cochrane Database of Systematic Reviews — surgical treatment for tubal disease in women due to undergo IVF (salpingectomy for hydrosalpinx).
• Human Fertilisation and Embryology Authority (HFEA), UK — fertility treatment trends and figures, age-banded live birth per embryo transferred.
• World Health Organization — laboratory manual reference values for semen analysis (describing natural conception, not IVF eligibility).
• The Assisted Reproductive Technology (Regulation) Act, 2021, and the PCPNDT Act, 1994 (India).